Developing novel peptides with health benefits involves significant costs and risks due to low success rates, which may deter investment.
But, supported by clinical trials, Dublin-based Nuritas has emerged as a leader in its field and has just closed an oversubscribed $42 million Series C funding round.
The funding will enable Nuritas to scale its operations, expand its global customer base worldwide.
The round was led by M&G Investments, on behalf of its Catalyst strategy—a purpose-led initiative supporting transformative businesses addressing global social and environmental challenges.
McWin Capital Partners, a private equity and venture capital firm focused on high-growth companies in the food ecosystem, also joined as a key investor. Current investors Grosvenor and ECBF also participated in the round.
Nutritional boost
The company uses advanced technologies, particularly AI and genomics, to discover and develop bioactive peptides – small proteins that can have significant health benefits. This approach allows Nuritas to create ingredients that enhance the nutritional value of food products.
The company specialises in plant-based peptides that can replace synthetic additives in food products, promoting a more natural approach to nutrition. It has established partnerships with companies in the food industry, such as Nestlé and Mars, to integrate its patented peptides into their products.
With nearly a decade of research, Nuritas has built a large peptide knowledge base. It claims it identifies peptides 10-50 times faster than traditional methods, with a clinical success rate of over 80%.
“Our mission is to improve the lives of billions by creating ingredients that address pressing global health challenges,” said Dr. Nora Khaldi, founder and CEO of Nuritas.
“Through our science-first approach, we are fundamentally shifting the paradigm of ingredient discovery, enabling our customers to deliver healthier, differentiated products that meet the needs of today’s consumers.”
